Management of hepatic metastases
Corresponding Author
Michael A. Choti
Departments of Surgery and Oncology, Johns Hopkins University School of Medicine, Baltimore, MD
Address reprint requests to Michael A. Choti, MD, Department of Surgery, Halsted 614, The Johns Hopkins Hospital, 600 North Wolfe St, Baltimore, MD 21287-4685Search for more papers by this authorGregory B. Bulkley
Departments of Surgery and Oncology, Johns Hopkins University School of Medicine, Baltimore, MD
Search for more papers by this authorCorresponding Author
Michael A. Choti
Departments of Surgery and Oncology, Johns Hopkins University School of Medicine, Baltimore, MD
Address reprint requests to Michael A. Choti, MD, Department of Surgery, Halsted 614, The Johns Hopkins Hospital, 600 North Wolfe St, Baltimore, MD 21287-4685Search for more papers by this authorGregory B. Bulkley
Departments of Surgery and Oncology, Johns Hopkins University School of Medicine, Baltimore, MD
Search for more papers by this authorAbstract
Although the liver is the most common site of metastatic disease from a variety of tumor types, isolated hepatic metastases most commonly occur from colorectal cancer and, less frequently, from neuroendocrine tumors, gastrointestinal sarcoma, ocular melanoma, and others. Complete evaluation of the extent of metastatic disease, both intrahepatically and extrahepatically, is important before considering treatment options. Based on a preponderance of uncontrolled studies for hepatic metastatic colorectal carcinoma, surgical resection offers the only potential for cure of selected patients with completely resected disease, with 5-year survival rates of 25% to 46%. Systemic and hepatic arterial infusion chemotherapy may be useful treatment options in patients with unresectable disease and possibly as an adjuvant treatment after liver resection. Other techniques of local tumor ablation, including cryotherapy and radiofrequency ablation, although promising, remain unproved. Management of hepatic metastases from neuroendocrine tumors and other noncolorectal primary tumors should be individualized based on the patient's clinical course, extent of disease, and symptoms.
References
- 1 Landis SH, Murray T, Bolden S, Wihgo PA. Cancer statistics, 1998. CA Cancer J Clin 1998; 48: 6–29. MEDLINE
- 2
Bengmark S,
Hafstrom L.
The natural history of primary and secondary malignant tumors of the liver. I. The prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy.
Cancer
1969;
23: 198–202.
MEDLINE
10.1002/1097-0142(196901)23:1<198::AID-CNCR2820230126>3.0.CO;2-J CAS PubMed Web of Science® Google Scholar
- 3 Oxley EM, Ellis H. Prognosis of carcinoma of the large bowel in the presence of liver metastases. Br J Surg 1969; 56: 149. MEDLINE
- 4 Wood CB, Gillis CR, Blumgart LH. A retrospective study of the natural history of patients with liver metastases from colorectal cancer. Clin Oncol 1976; 2: 285–288. MEDLINE
- 5 Bengtsson G, Carlsson G, Hafstom L, Jonsson P-E. Natural history of patients with untreated liver metastases from colorectal cancer. Am J Surg 1981; 141: 586. MEDLINE
- 6 Adson MA, van Heerden JA, Adson MH, Wagner JS, Ilstrup DM. Resection of hepatic metastases from colorectal cancer. Arch Surg 1984; 119: 647–651. MEDLINE
- 7 Ihse I, Persson B, Tibblin S. Neuroendocrine metastases of the liver. World J Surg 1995; 19: 76–82. MEDLINE
- 8
Moertel CG,
Sauer WG,
Dockerty MB,
Baggenstoss AH.
Life history of the carcinoid tumor of the small intestine.
Cancer
1961;
14: 901–912.
10.1002/1097-0142(196109/10)14:5<901::AID-CNCR2820140502>3.0.CO;2-Q CAS PubMed Web of Science® Google Scholar
- 9 Moertel CG. Karnofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol 1987; 5: 1503–1522.
- 10 Thompson GB, van Heerden JA, Grant CS, Carney JA, Ilstrup DM. Islet cell carcinomas of the pancreas: A twenty-year experience. Surgery 1988; 104: 1011–1017. MEDLINE
- 11 Declore R, Friesen SR. Gastrointestinal neuroendocrine tumors. J Am Coll Surg 1994; 178: 188–211.
- 12
Godwin JD.
Carcinoid tumors: An analysis of 2837 cases.
Cancer
1975;
36: 560–569.
MEDLINE
10.1002/1097-0142(197508)36:2<560::AID-CNCR2820360235>3.0.CO;2-4 PubMed Web of Science® Google Scholar
- 13 Sjoblom SM. Clinical presentation and prognosis of gastrointestinal carcinoid tumours. Scand J Gastroenterol 1988; 23: 779–787. MEDLINE
- 14 Povoski SP, Fong Y, Sgouros SC, Kemeny N, Downey RJ, Blumgart LH. Role of chest CT in patients with negative chest X-rays referred for hepatic colorectal metastases. Ann Surg Oncol 1998; 5: 9–15. MEDLINE
- 15 McAfee MK, Allen MS, Trastek VF, Ilstrup DM, Deschamps C, Pairolero PC. Colorectal lung metastases: Results of surgical excision. Ann Thorac Surg 1992; 53: 780–785. MEDLINE
- 16 Wade TP, Virgo KS, Li MJ, Callander PW, Longo WE, Johnson FE. Outcomes after detection of metastatic carcinoma of the colon and rectum in a national hospital system. J Am Coll Surg 1996; 82: 353–361.
- 17 Gross BH, Glazer GM, Bookstein FL. Multiple pulmonary nodules detected by computed tomography: Diagnostic implications. J Comput Assist Tomogr 1985; 9: 880–885. MEDLINE
- 18 Miller DL, Simmons JT, Chang R, Ward BA, Shawker TH, Doppman JL, et al. Hepatic metastasis detection: Comparison of three CT contrast enhancement methods. Radiology 1987; 165: 785–790. MEDLINE
- 19 Sardi A, Agnone CM, Nieroda CA, Mojzisik C, Hinkle G, Ferrara P, et al. Radioimmunoguided surgery in recurrent colorectal cancer: The role of carcinoembryonic antigen, computerized tomography, and physical examination. South Med J 1989; 82: 1235–1244. MEDLINE
- 20 Vassiliades VG, Foley WD, Alarcon J, Lawson T, Erickson S, Kneeland JB, et al. Hepatic metastases: CT vs MR imaging at 1.5T. Gastrointest Radiol 1991; 16: 159–163. MEDLINE
- 21 Sugarbaker PH, Gianola FJ, Dwyer MD, Newman NR. A simplified plan for follow-up of patients with colon and rectal cancer supported by prospective studies of laboratory and radiologic test results. Surgery 1987; 102: 79–87. MEDLINE
- 22 Strauss L, Clorius J, Schlag P, Lehner B, Kimmig B, Engenhart R, et al. Recurrence of colorectal tumors: PET evaluation. Radiology 1989; 170: 329–332. MEDLINE
- 23 Ogunbiyi OA, Flanagan FL, Dehdashti F, Siegel BA, Trask DD, Birnbaum EH, et al. Detection of recurrent and metastatic colorectal cancer: Comparison of positron emission tomography and computed tomography. Ann Surg Oncol 1997; 4: 613–620. MEDLINE
- 24 Ito K, Kato T, Tadokoro M, Ishiguchi T, Oshima M, Ishigaki T, et al. Recurrent rectal cancer and scan: Differentiation with PET and MR imaging. Radiology 1992; 182: 549–552. MEDLINE
- 25 Schiepers C, Pennick F, De Vadder N, Merck E, Mortelmans L, Bormans G, et al. Contribution of PET in the diagnosis of recurrent colorectal cancer: Comparison with conventional imaging. Eur J Surg Oncol 1995; 21: 517–522. MEDLINE
- 26 Beets F, Penninckz F, Schiepers C, Filez L, Mortelmans L, Kerremans R, et al. Clinical value of whole-body positron emission tomography with [18F]fluorodeoxyglucose in recurrent colorectal cancer. Br J Surg 1994; 81: 1666–1670. MEDLINE
- 27 Goldberg MA, Lee MJ, Fischman AJ, Mueller PR, Alpert NM, Thrall JH. Fluorodeoxyglucose PET of abdominal and pelvic neoplasms: Potential role in oncologic imaging. Radiographics 1993; 13: 1047–1062. MEDLINE
- 28 Dominguez JM, Wolff BG, Nelson H, Forstrom LA, Mullan BP. 111In-CYT-103 scanning in recurrent colorectal cancer—Does it affect standard management? Dis Colon Rectum 1996; 39: 514–519. MEDLINE
- 29 Doerr RJ, Abdel-Nabi H, Merchant B. Indium 111 ZCE-025 immunoscintigraphy in occult recurrent colorectal cancer with elevated carcinoembryonic antigen level. Arch Surg 1990; 125: 226–229. MEDLINE
- 30 Doerr RJ, Abdel-Nabi H, Krag D, Mitchell E. Radiolabeled antibody imaging in the management of colorectal cancer. Ann Surg 1991; 214: 118–124. MEDLINE
- 31 Schneebaum S, Papo J, Graif M, Baratz M, Baron J, Skornik Y. Radioimmunoguided surgery benefits for recurrent colorectal cancer. Ann Surg Oncol 1997; 4: 371–376. MEDLINE
- 32 Takenoshita S, Hashizume T, Asao T, Nakamura J, Katoh R, Oriuchi N, et al. Immunoscintigraphy using 99mTc-labeled anti-CEA monoclonal antibody for patients with colorectal cancer. Anticancer Res 1995; 15: 471–475. MEDLINE
- 33 Clarke MP, Kane RA, Steele G, Hamilton ES, Ravikumar TS, Onik G, et al. Prospective comparison of preoperative imaging and intraoperative ultrasonography in the detection of liver tumors. Surgery 1989; 106: 849–855. MEDLINE
- 34 Kuszyk BS, Bluemke DA, Urban BA, Choti MA, Hruban RH, Sitzmann JV, et al. Portal-phase contrast enhanced helical CT for the detection of malignant hepatic tumors: Sensitivity based on comparison with intraoperative and pathologic findings. AJR Am J Roentgenol 1996; 166: 91–95. MEDLINE
- 35 Bluemke DA, Soyer PA, Chan BW, Bliss DF, Calhoun PS, Fishman EK. Spiral CT during arterial portography: Technique and applications. Radiographics 1995; 15: 623–637. MEDLINE
- 36 Bluemke DA, Soyer P, Fishman EK. Helical (spiral) CT of the liver. Radiol Clin North Am 1995; 33: 863–886. MEDLINE
- 37 Rubin GD, Dake MD, Semba CP. Current status of three-dimensional spiral CT scanning for imaging the vasculature. Radiol Clin North Am 1995; 33: 51–70. MEDLINE
- 38 Zeman RK, Fox SH, Silverman PM, Davros WJ, Carter LM, Griego D, et al. Helical (spiral) CT of the abdomen. AJR Am J Roentgenol 1993; 160: 719–725. MEDLINE
- 39 Baron RL. Understanding and optimizing use of contrast material of CT of the liver. AJR Am J Roentgenol 1994; 163: 323–331. MEDLINE
- 40 Soyer P, Bluemke DA, Fishman EK. CT during arterial portography for the preoperative evaluation of hepatic tumors: How, when, and why? AJR Am J Roentgenol 1994; 163: 1325–1331. MEDLINE
- 41 Soyer P, Levesque M, Elias D, Zeitoun G, Roche A. Preoperative assessment of resectability of hepatic metastases from colonic carcinoma: CT portography vs sonography and dynamic CT. AJR Am J Roentgenol 1992; 159: 741–744. MEDLINE
- 42 Soyer P, Lacheheb D, Levesque M. False-positive CT portography: Correlation with pathologic findings. Am J Roentgenol Radium Ther Nucl Med 1993; 160: 285–289.
- 43 Nelson RC, Chezmar JL, Sugerbaker PH, Bernardino ME. Hepatic tumors: Comparison of CT during arterial portography, delayed CT, and MR imaging for preoperative evaluation. Radiology 1989; 172: 27–34. MEDLINE
- 44 Soyer P, Bluemke DA, Hruban RH, Sitzmann JV, Fishman EK. Hepatic metastases from colorectal cancer: Detection and false-positive findings with helical CT during arterial portography. Radiology 1994; 193: 71–74. MEDLINE
- 45 Vogel SB, Drane WE, Ros PR, Kerns SR, Bland KI. Prediction of surgical resectability in patients with hepatic colorectal metastases. Ann Surg 1994; 219: 508–514. MEDLINE
- 46 McFarland EG, Mayo-Smith WW, Saini S, Hahn PF, Goldberg MA, Lee MJ. Hepatic hemangiomas and malignant tumors: Improved differentiation with heavily T2-weighted conventional spin echo MR imaging. Radiology 1994; 193: 43–47. MEDLINE
- 47 Lee MJ, Saini S, Hamm B, Taupitz M, Hahn PF, Seneterre E, et al. Focal nodular hyperplasia of the liver: MR findings in 35 proven cases. AJR Am J Roentgenol 1991; 156: 317–320. MEDLINE
- 48 Rummeny EJ, Wernecke K, Saini S, Vassallo P, Wiesmann W, Oestmann JW, et al. Comparison between high-field-strength MR imaging and CT for screening of hepatic metastases: A receiver operating characteristic analysis. Radiology 1992; 182: 879–886. MEDLINE
- 49 Hagspiel KD, Neidl KF, Eichenberger AC, Weder W, Marincek B. Detection of liver mestastases: Comparison of superparamagnetic iron oxide-enhanced and unenhanced MR imaging at 1.5 T with dynamic CT, intraoperative US, and percutaneous US. Radiology 1995; 196: 471–478. MEDLINE
- 50 Seneterre E, Taourel P, Bouvier Y, Prodel J, Van Beers B, Daures JP, et al. Detection of hepatic metastases: Ferumoxides-enhanced MR imaging versus unenhanced MR imaging and CT during arterial portography. Radiology 1996; 200: 785–792. MEDLINE
- 51 Van Beers BE, Gallez B, Pringot J. Contrast-enhanced MR imaging of the liver. Radiology 1997; 203: 297–306. MEDLINE
- 52 Ansfield F, Schroeder JM, Curreri AR. Five years experience with 5-fluorouracil. JAMA 1962; 181: 295.
- 53 Christophidis N, Vajda FJE, Lucas I, Drummer O, Moon WJ, Louis WJ. Fluorouracil therapy in patients with carcinoma of the large bowel: A pharmacokinetic comparison of various rates and routes of administration. Clin Pharmacokinet 1978; 3: 330–336. MEDLINE
- 54 Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A mid-Atlantic oncology program study. J Clin Oncol 1989; 7: 425–432. MEDLINE
- 55 Leichman CC, Fleming TR, Muggia FM, Tangen CM, Ardalan B, Doroshow JH, et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group study. J Clin Oncol 1995; 13: 1303–1311. MEDLINE
- 56 Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 1992; 10: 896–903. MEDLINE
- 57 Rougier P, Bugat R, Douillard JY, Culine S, Suc E, Brunet P, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997; 15: 251–260. MEDLINE
- 58 Shimada Y, Rougier P, Pitot H. Efficacy of CPT-11 (irinotecan) as a single agent in metastatic colorectal cancer. Eur J Cancer 1996; 32A: S13–S17. MEDLINE
- 59 Rothenberg ML. CPT-11: An original spectrum of clinical activity. Semin Oncol 1996; 23: 21–26. MEDLINE
- 60 Conti JA, Kemeny NE, Saltz LB, Huang Y, Tong WP, Chou TC, et al. Irinotecan is an active agent in untreated patients with metastic colorectal cancer. J Clin Oncol. 1996; 14: 709–715. MEDLINE
- 61 Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil, or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992; 326: 519–523. MEDLINE
- 62 Jacobsen MB, Hanssen LE. Clinical effects of octreotide compared to placebo in patients with gastrointestinal neuroendocrine tumors. J Int Med 1995; 237: 269–275.
- 63 Woodington GF, Waugh JM. Results of resection of metastatic tumors of the liver. Am J Surg 1963; 105: 24–29.
- 64 Zieren HU, Muller JM, Zieren J, Pichlmaier H. The impact of patient's age on surgical therapy of colorectal liver metastases. Int Surg 1993; 78: 288–291. MEDLINE
- 65 Hughes KS, Simon R, Songhorabodi S, Adson MA, Ilstrup DM, Fortner JG, et al. Resection of the liver for colorectal carcinoma metastases: A multi-institutional study of patterns of recurrence. Surgery 1986; 100: 278–284. MEDLINE
- 66 Paul M, Mulder S, Cuesta M, Sikkenk AC, Lyesen GK, Meijer S. Impact of intraoperative ultrasonography on treatment strategy for colorectal cancer. Br J Surg 1994; 81: 1660–1663. MEDLINE
- 67 Fortunato L, Clair M, Hoffman J, Sigurdson ER, Sauter ER, Barber LW, et al. Is CT portography (CTAP) really useful in patients with liver tumors who undergo intraoperative ultrasonography (IOUS)? Am Surg 1995; 61: 560–564. MEDLINE
- 68
van Dijkum EJ,
de Wit LT,
van Delden OM,
Rauws EA,
van Lanschot JJ,
Obertop H, et al.
The efficacy of laparoscopic staging in patients with upper gastrointestinal tumors.
Cancer
1997;
79: 1315–1319.
MEDLINE
10.1002/(SICI)1097-0142(19970401)79:7<1315::AID-CNCR7>3.0.CO;2-F CAS PubMed Web of Science® Google Scholar
- 69 John TG, Greig JD, Crosbie JL, Miles WF, Garden OJ. Superior staging of liver tumors with laparoscopy and laparoscopic ultrasound. Ann Surg 1994; 220: 711–719. MEDLINE
- 70 Schlag P, Hohenberger P, Herfath C. Resection of liver metastases in colorectal cancer: Competitive analysis of treatment results in synchronous versus metachronous metastases. Eur J Surg Oncol 1990; 16: 360–365. MEDLINE
- 71 Doci R, Gennari L, Bignami P, Montalto F, Morabito A, Bozzetti F. One hundred patients with hepatic metastases from colorectal cancer treated by resection: Analysis of prognostic determinants. Br J Surg 1991; 78: 797–801. MEDLINE
- 72 Scheele J, Stangle R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: Impact of surgical resection on natural history. Br J Surg 1990; 77: 1241–1246. MEDLINE
- 73 Fong Y, Cohen AM, Fortner JG, Enker WE, Turnbull AD, Coit DG, et al. Liver resection for colorectal metastases. J Clin Oncol 1997; 15: 938–946. MEDLINE
- 74 Taylor M, Forster J, Langer B, Taylor BR, Greig PD, Mahut C. A study of prognostic factors for hepatic resection for colorectal metatases. Am J Surg 1997; 173: 467–471. MEDLINE
- 75 Choti MA, Bowman HM, Pitt HA, Sosa JA, Sitzmannn JV, Cameron JL, Gordon TA. Should hepatic resections be performed at high-volume referral centers? J Gastrointest Surg 1998; 2: 11–20. MEDLINE
- 76 Fuhrman GM, Curley SA, Hohn DC, Roh MS. Improved survival after resection of colorectal liver metastases. Ann Surg Oncol 1995; 2: 537–541. MEDLINE
- 77 Hughes KS, Rosenstein RB, Songhorabodi S, Adson MA, Istrup DM, Fortner JG, et al. Resection of the liver for colorectal carcinoma metastases: A multi-institutional study of long-term survivors. Dis Colon Rectum 1988; 31: 1–4. MEDLINE
- 78 Rosen CB, Nagorney DM, Taswell HF, Helgeson SL, Ilstrup DM, van Heerden JA, et al. Perioperative blood transfusion and determinants of survival after liver resection for metastatic colorectal carcinoma. Ann Surg 1992; 216: 492–505.
- 79 Wolf RF, Goodnight JE, Krag DE, Schneider PD. Results of resection and proposed guidelines for patient selection in instances of non-colorectal hepatic metastases. Surg Gynecol Obstet 1991; 173: 454–460. MEDLINE
- 80 Que FG, Nagorney DM, Batts KP, Linz LJ, Evols LK. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 1995; 169: 36–43. MEDLINE
- 81 Chen H, Hardacre JM, Uzar A, Cameron JL, Choti MA. Isolated liver metastases from neuroendocrine tumors: Does resection prolong survival? J Am Coll Surg 1998; 187: 88–93. MEDLINE
- 82 McEntee FP, Nagorney DM, Kvol LK, Moertel CG. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 1990; 108: 1091–1096. MEDLINE
- 83 Harrison LE, Brennan MF, Newman E, Fortner JG, Picardo A, Blumgart LH, et al. Hepatic resection for noncolorectal, nonneuroendocrine metastases: A fifteen-year experience with ninety-six patients. Surgery 1997; 121: 625–632. MEDLINE
- 84 Morrow CE, Grage TB, Sutherland DE, Najarian JS. Hepatic resection for secondary neoplasms. Surgery 1982; 92: 610–614. MEDLINE
- 85 Thompson HH, Tompkins RK, Longmire WPJ. Major hepatic resection. A 25-year experience. Ann Surg 1983; 197: 375–388. MEDLINE
- 86 Stehlin JSJ, de Ipolyi PD, Greeff PJ, McGaff CJJ, Davis BR, McNary L. Treatment of cancer of the liver. Twenty years' experience with infusion and resection in 414 patients. Ann Surg 1988; 208: 23–35. MEDLINE
- 87 Bozzetti F, Doci R, Bignami P, Morabito A, Gennari L. Patterns of failure following surgical resection of colorectal cancer liver metastases. Rationale for a multimodal approach. Ann Surg 1987; 205: 264–270. MEDLINE
- 88 Ekberg H, Tranberg KG, Andersson R, Lundstedt C, Hagerstrand I, Ranstam J, et al. Pattern of recurrence in liver resection for colorectal secondaries. World J Surg 1987; 11: 541–547. MEDLINE
- 89 Stone MD, Cady B, Jenkins RL, McDermott WV, Steele GDJ. Surgical therapy for recurrent liver metastases from colorectal cancer. Arch Surg 1990; 125: 718–721. MEDLINE
- 90 Cady B, Jenkins RL, Steele GDJ, Lewis WD, Stone MD, McDermott WV, et al. Surgical margin in hepatic resection for colorectal metastasis: A critical and improvable determinant of outcome. Ann Surg 1998; 227: 566–571. MEDLINE
- 91 Griffith KD, Sugarbaker PH, Chang AE. Repeat hepatic resections for colorectal metastases. Surgery 1990; 107: 101–104. MEDLINE
- 92 Nordlinger B, Vaillant JC, Guiguet M, Balladur P, Paris F, Bachellier P, et al. Survival benefit of repeat liver resections for recurrent colorectal metastases: 143 cases. Association Francaise de Chirurgie. J Clin Oncol 1994; 12: 1491–1496. MEDLINE
- 93 Bismuth H, Adam R, Navarro F, Castaing D, Engerran L, Abascal A. Re-resection for colorectal liver metastasis. Surg Oncol Clin North Am 1996; 5: 353–364.
- 94 Fong Y, Blumgart LH, Cohen A, Fortner J, Brennan MF. Repeat hepatic resections for metastatic colorectal cancer. Ann Surg 1994; 220: 657–662. MEDLINE
- 95 Vaillant JC, Balladur P, Nordlinger B, Karaitianos I, Hannoun L, Huguet C, et al. Repeat liver resection for recurrent colorectal metastases. Br J Surg 1993; 80: 340–344. MEDLINE
- 96 Elias D, Lasser P, Hoang JM, Leclere J, Debaene B, Bognel C, et al. Repeat hepatectomy for cancer. Br J Surg 1993; 80: 1557–1562. MEDLINE
- 97 Fernandez-Trigo V, Shamsa F, Aldrete J, Andersson R, Arnaud JP, Bergamaschi R, et al. Repeat liver resections from colorectal metastasis. Repeat Hepatic Resection Registry. Cancer Treat Res 1994; 69: 185–196. MEDLINE
- 98 Penn I. Hepatic transplantation for primary and metastatic cancers of the liver. Surgery 1991; 110: 726–734. MEDLINE
- 99 Le Treut YP, Delpero JR, Dousset B, Cherqui D, Segol P, Mantion G, et al. Results of liver transplantation in the treatment of metastatic neuroendocrine tumors. A 31-case French multicentric report. Ann Surg 1997; 225: 355–364. MEDLINE
- 100 Lang H, Oldhafer KJ, Weimann A, Schlitt HJ, Scheumann GF, Fleming P, et al. Liver transplantation for metastatic neuroendocrine tumors. Ann Surg 1997; 225: 347–354. MEDLINE
- 101 Routley D, Ramage JK, McPeake J, Tan KC, Williams R. Orthotopic liver transplantation in the treatment of metastatic neuroendocrine tumors of the liver. Liver Transplant Surg 1995; 1: 118–121.
- 102 Fortner JG, Silva JS, Cox EB, Golbey RB, Gallowitz H, Maclean BJ. Multivariate analysis of a personal series of 247 patients with liver metastases from colorectal cancer. Ann Surg 1984; 199: 317–323. MEDLINE
- 103 Patt YZ. Regional hepatic arterial chemotherapy for colorectal cancer metastatic to the liver: The controversy continues. J Clin Oncol 1993; 11: 815–819. MEDLINE
- 104 Moriya Y, Sugihara K, Hojo K, Makuuchi M. Adjuvant hepatic intra-arterial chemotherapy after potentially curative hepatectomy for liver metastases from colorectal cancer: A pilot study. Eur J Surg Oncol 1991; 17: 519–525. MEDLINE
- 105 Curley SA, Roh MS, Chase JL, Hohn DC. Adjuvant hepatic arterial infusion chemotherapy after curative resection of colorectal liver metastases. Am J Surg 1993; 166: 743–748. MEDLINE
- 106
Kemeny MM,
Goldberg D,
Beatty JD,
Blayney D,
Browning S,
Doroshow J, et al.
Results of a prospective randomized trial of continuous regional chemotherapy and hepatic resection as treatment of hepatic metastases from colorectal primaries.
Cancer
1986;
57: 492–498.
MEDLINE
10.1002/1097-0142(19860201)57:3<492::AID-CNCR2820570315>3.0.CO;2-M PubMed Web of Science® Google Scholar
- 107 Gage AG. Cryosurgery in the treatment of cancer. Surg Gynecol Obstet 1992; 174: 73–92. MEDLINE
- 108 Ravikumar TS, Kane R, Cady B, Jenkins R, Clouse M, Steele G. A 5-year study of cryosurgery in the treatment of liver tumors. Arch Surg 1991; 126: 1520–1524. MEDLINE
- 109 Morris DL, Horton MD, Dilley AV, Warlters A, Clingan PR. Treatment of hepatic metastases by cryotherapy and regional cytotoxic perfusion. Gut 1993; 34: 1156–1157. MEDLINE
- 110 Adam R, Alpinar E, Johann M, Kunstlinger F, Majno P, Bismuth H. Place of cryosurgery in the treatment of malignant liver tumors. Ann Surg 1997; 225: 39–48. MEDLINE
- 111
Cozzi PJ,
Englund R,
Morris DL.
Cryotherapy treatment of patients with hepatic metastases from neuroendocrine tumors.
Cancer
1995;
76: 501–509.
MEDLINE
10.1002/1097-0142(19950801)76:3<501::AID-CNCR2820760322>3.0.CO;2-X CAS PubMed Web of Science® Google Scholar
- 112 Matsukawa T, Yamashita Y, Arakawa A, Nishiharu T, Urata J, Murakami R, et al. Percutaneous microwave coagulation therapy in liver tumors. Acta Radiol 1997; 38: 410–415. MEDLINE
- 113 Nagata Y, Hiraoka M, Nishimura Y, Masunaga S, Mitumori M, Okuno Y, et al. Clinical results of radiofrequency hyperthermia for malignant liver tumors. Int J Radiat Oncol Biol Phys 1997; 38: 359–365. MEDLINE
- 114 Prat F, Centarti M, Sibille A, Abou el Fadil FA, Henry L, Chapelon JY, et al. Extracorporeal high-intensity focused ultrasound for VX2 liver tumors in the rabbit. Hepatology 1995; 21: 832–836. MEDLINE
- 115 Lau WY, Leung WT, Ho S, Leung NW, Chan M, Lin J, et al. Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: A phase I and II study. Br J Cancer 1994; 70: 944–949.
- 116 Livraghi T, Lazzaroni S, Meloni F, Torzilli G, Vettori C. Intralesional ethanol in the treatment of unresectable liver cancer. World J Surg 1995; 19: 801–806. MEDLINE
- 117 Hajarizadeh H, Ivancev K, Mueller CR, Fletcher WS, Woltering EA. Effective palliative treatment of metastatic carcinoid tumors with intra-arterial chemotherapy/chemoembolization combined with octreotide acetate. Am J Surg 1992; 163: 479–483. MEDLINE
- 118 Perry LJ, Stuart K, Stokes KR, Clouse ME. Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Surgery 1994; 166: 1111–1117.
- 119 Ruszniewski P, Rougier P, Roche A, Legmann P, Sibert A, Hochlaf S, et al. Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. Cancer 1993; 71: 2623–2630.
- 120 Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol 1954; 30: 227–232.
- 121 Healy JE. Vascular patterns in human metastic liver tumors. Surg Gynecol Obstet 1965; 120: 1187–1193.
- 122 Lien WM, Ackerman NB. The blood supply of experimental liver metastases. II. A microcirculatory study of the normal and tumor vessels of the liver with the use of perfused silicone rubber. Surgery 1970; 68: 334–340. MEDLINE
- 123 Lin B, Lunderquist A, Hagerstrand L, Boijsen E. Postmortem examination of the blood supply and vascular pattern of small liver metastases in man. Surgery 1984; 96: 517–526. MEDLINE
- 124 Kemeny N, Cohen A, Seiter K, Conti JA, Sigurdson ER, Tao Y, et al. Randomized trial of hepatic arterial floxuridine, mitomycin, and carmustine versus floxuridine alone in previously treated patients with liver metastases form colorectal cancer. J Clin Oncol 1993; 11: 330–335. MEDLINE
- 125 Kemeny N, Daly J, Reichman B, Geller N, Botet J, Oderman P. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. Ann Intern Med 1987; 107: 459–465. MEDLINE
- 126 Hohn DC, Stagg RJ, Friedman MA, Hannigan JF, Rayner A, Ignoffo RJ, et al. A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: The Northern California Oncology Group trial. J Clin Oncol 1989; 7: 1646–1654. MEDLINE
- 127 Chang AE, Schneider PD, Sugarbaker PH, Simpson C, Culnane M, Steinberg SM. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 1987; 206: 685–693. MEDLINE
- 128 Martin JK, O'Connell MJ, Wieand HS, Fitzgibbons RJ, Mailliard JA, Rubin J, et al. Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. Arch Surg 1990; 125: 1022–1027. MEDLINE
- 129 Rougier P, Laplanche A, Huguier M, Hay JM, Ollivier JM, Escat J, et al. Hepatic arterial infusion of floxuridine in patients with liver metastases form colorectal carcinoma: Long-term results of a prospective randomized trial. J Clin Oncol 1992; 10: 1112–1118. MEDLINE
- 130 Meta-Analysis Group in Cancer. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst 1996; 88: 252–258. MEDLINE
- 131
Kemeny N,
Seiter K,
Conti JA,
Cohen A,
Bertino JR,
Sigurdson ER, et al.
Hepatic arterial floxuridine and leucovorin for unresectable liver metastases from colorectal carcinoma. New dose schedules and survival update.
Cancer
1994;
73: 1134–1142.
MEDLINE
10.1002/1097-0142(19940215)73:4<1134::AID-CNCR2820730403>3.0.CO;2-V PubMed Web of Science® Google Scholar
- 132 Hohn DC, Stagg RJ, Price DC, Lewis BJ. Avoidance of gastroduodenal toxicity in patients receiving hepatic arterial 5-fluoro-2-deoxyuridine. J Clin Oncol 1985; 3: 1257–1260. MEDLINE
- 133
Kemeny N,
Seiter K,
Niedzwiecki D,
Chapman D,
Sigurdson E,
Cohen A, et al.
A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer.
Cancer
1992;
69: 327–334.
MEDLINE
10.1002/1097-0142(19920115)69:2<327::AID-CNCR2820690209>3.0.CO;2-U CAS PubMed Web of Science® Google Scholar
- 134
Doria MI,
Shepard KV,
Levin B,
Riddell RH.
Liver pathology following hepatic arterial infusion chemotherapy.
Cancer
1986;
58: 855–861.
MEDLINE
10.1002/1097-0142(19860815)58:4<855::AID-CNCR2820580409>3.0.CO;2-6 PubMed Web of Science® Google Scholar
- 135 Petrelli N, Herrera L, Rustum Y, Burke P, Creaven P, Stulc J, et al. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 1987; 5: 1559–1565. MEDLINE
- 136 Valone FH, Friedman MA, Wittlinger PS, Drakes T, Eisenberg PD, Malec M, et al. Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: A randomized trial of the Northern California Oncology Group. J Clin Oncol 1989; 7: 1427–1436. MEDLINE
- 137 Ehrlichman C, Fine S, Wong A, Elhakim T. Randomized trial of fluorouracil and folinc acid in patients with metastic colorectal carcinoma. J Clin Oncol 1988; 6: 469–475. MEDLINE
- 138 Petrelli N, Douglass HO, Herrera L, Russell D, Stablein DM. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III trial. J Clin Oncol 1989; 7: 1419–1426. MEDLINE
- 139
O'Connell MJ.
A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced coloretal cancer. A Mayo Clinic/North Central Cancer Treatment Group study.
Cancer
1989;
63: 1026–1030.
MEDLINE
10.1002/1097-0142(19890315)63:6+<1026::AID-CNCR2820631307>3.0.CO;2-R PubMed Web of Science® Google Scholar
- 140 Doroshow JH, Multhauf P, Leong L, Margolin K, Litchfield T, Akman S, et al. Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. J Clin Oncol 1990; 8: 491–501. MEDLINE
- 141 Nobile M, Canobbio L, Sobrero A, Galligioni E, Vidili MG, Fassio T, et al. A randomized trial of 5-fluorouracil alone versus 5-fluorouracil and high-dose leucovorin in untreated advanced colorectal cancer patients. Adv Exp Med Biol 1988; 244: 213–218. MEDLINE
- 142 Labianca R, Pancera G, Aitini E, Barni S, Beretta A, Beretta GD, et al. Folinic acid + 5-fluorouracil (5-FU) versus equidose 5-FU in advanced colorectal cancer. Phase III study of “GISCAD” (Italian Group for the Study of Digestive Tract Cancer). Ann Oncol 1991; 2: 673–679. MEDLINE
- 143 Di Costanzo F, Bartolucci R, Calabresi F, Sofra M, Marzola M, Belsanti V, et al. Fluorouracil-alone vs high-dose folinic acid and fluorouracil in advanced colorectal cancer: Randomized trial of the Italian Oncology Group for Clinical Research (GOIRC). Ann Oncol 1992; 3: 371–376. MEDLINE
- 144 Steinke B, Gunther E, Hirschmann WD, Sondern W, Koniczek KH, Wander HE, et al. Fluorouracil versus folinic acid/fluorouracil in advanced colorectal cancer—Preliminary results of a randomized trial. Semin Oncol 1992; 19: 141–147. MEDLINE
- 145 Martoni A, Cricca A, Guaraldi M, Covizzi M, Farris A, Pannuti F. Weekly regimen of 5-FU vs 5-FU + intermediate dose folinic acid in the treatment of advanced colorectal cancer. Anticancer Res 1992; 12: 607–612. MEDLINE
- 146 Bobbio-Pallavicini E, Porta C, Moroni M, Spaghi A, Casagranda I, Nastasi G. Folinic acid does improve 5-fluorouracil activity in vivo. Results of a phase III study comparing 5-fluorouracil to 5-fluorouracil and folinic acid in advanced colon cancer patients. J Chemother 1993; 5: 52–55. MEDLINE
- 147 Tuttle TM, Curley SA, Roh MS. Repeat hepatic resection as effective treatment of recurrent colorectal liver metastases. Ann Surg Oncol 1997; 4: 125–130. MEDLINE
- 148 Adam R, Bismuth H, Castaing D, Waechter F, Navarro F, Abascal A, et al. Repeat hepatectomy for colorectal liver metastases. Ann Surg 1997; 225: 51–60. MEDLINE